Vor Biopharma’s (VOR) Outperform Rating Reiterated at Oppenheimer

Vor Biopharma (NYSE:VOR)‘s stock had its “outperform” rating reiterated by analysts at Oppenheimer in a report issued on Friday,Benzinga reports. They currently have a $8.00 price target on the stock.

A number of other research analysts have also commented on the stock. Stifel Nicolaus dropped their price objective on shares of Vor Biopharma from $12.00 to $5.00 and set a “buy” rating on the stock in a research note on Friday. JMP Securities reaffirmed a “market outperform” rating and set a $12.00 price objective on shares of Vor Biopharma in a research note on Tuesday, December 10th. Wedbush reiterated an “outperform” rating and issued a $7.00 target price on shares of Vor Biopharma in a research note on Thursday. Finally, HC Wainwright cut their price target on Vor Biopharma from $17.50 to $13.00 and set a “buy” rating for the company in a research note on Friday. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $8.86.

Vor Biopharma Stock Up 1.2 %

VOR traded up $0.01 on Friday, reaching $0.86. The company had a trading volume of 30,566 shares, compared to its average volume of 591,501. Vor Biopharma has a 1 year low of $0.63 and a 1 year high of $2.43. The stock has a market capitalization of $59.20 million, a PE ratio of -0.52 and a beta of -0.40. The stock has a 50-day moving average price of $1.23 and a 200-day moving average price of $1.01.

Institutional Trading of Vor Biopharma

Several large investors have recently added to or reduced their stakes in VOR. GABELLI & Co INVESTMENT ADVISERS INC. acquired a new position in Vor Biopharma during the 4th quarter worth approximately $33,000. Virtu Financial LLC purchased a new stake in shares of Vor Biopharma during the fourth quarter valued at approximately $60,000. XTX Topco Ltd acquired a new position in shares of Vor Biopharma during the fourth quarter worth $80,000. Trustees of Columbia University in the City of New York purchased a new position in shares of Vor Biopharma in the fourth quarter valued at $102,000. Finally, Northern Trust Corp grew its holdings in Vor Biopharma by 39.0% during the 4th quarter. Northern Trust Corp now owns 157,617 shares of the company’s stock valued at $175,000 after purchasing an additional 44,252 shares in the last quarter. 97.29% of the stock is currently owned by institutional investors and hedge funds.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.